Nephrology – Page 7

Perioperative Nitric Oxide Conditioning in Cardiac Surgery: A Paradigm Shift for Protecting Renal Function in CKD Patients (DEFENDER Trial Review)

By MedXY 08/21/2025

Perioperative nitric oxide administration in CKD patients undergoing cardiac surgery significantly reduces acute kidney injury incidence and preserves renal function, while demonstrating safety and additional benefits against postoperative pneumonia.

Clinical Updates Nephrology news Specialties

Efficacy and Safety of Anrikefon in Haemodialysis Patients with Pruritus: Insights from a Phase 3 Multicentre Randomised Controlled Trial

By MedXY 08/21/2025

This phase 3 trial demonstrates that anrikefon significantly reduces pruritus intensity and improves quality of life in patients undergoing haemodialysis with moderate to severe chronic kidney disease-associated pruritus, with a favorable safety profile.

Cardiology Nephrology Specialties

Comparative Effectiveness of Prasugrel Versus Clopidogrel in Patients with Impaired Renal Function: A Clinical Review

By MedXY 08/21/2025

Prasugrel demonstrates a more rapid and significant inhibition of platelet aggregation than clopidogrel in patients with stable coronary artery disease and impaired renal function, particularly within the first week of therapy.

Infectious Diseases Nephrology news Respiratory Specialties

Kidney-transplant recipients benefit from COVID-19 vaccination

By MedXY 08/20/2025

Kidney-transplant recipients on long-term kidney replacement therapy demonstrate significant reductions in COVID-19-related hospitalizations and mortality following three or more vaccine doses, supporting booster vaccinations in this vulnerable population.

Cardiology Clinical Updates Nephrology news Specialties

Unraveling Molecular Links Between Chronic Kidney Disease and Heart Failure via the Plasma Proteome

By MedXY 08/17/2025

A comprehensive proteomic analysis from the ARIC study identifies plasma proteins linking kidney dysfunction to incident heart failure, highlighting potential biomarkers and therapeutic targets for HF prevention in CKD patients.

AI Clinical Updates Nephrology news Specialties

Evaluating Electronic Nudges to Enhance Guideline-Directed Therapy in Chronic Kidney Disease: Insights from the NUDGE-CKD Trial

By MedXY 08/16/2025

The NUDGE-CKD trial found that electronic letter-based nudges to patients with chronic kidney disease and their general practitioners did not significantly improve initiation of guideline-recommended medications over usual care.

Cardiology Diabetes & Endocrinology Nephrology Specialties

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

By MedXY 08/16/2025

The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.

Cardiology Clinical Updates Nephrology news Specialties

Delayed Remote Ischemic Preconditioning Reduces Contrast-Associated Acute Kidney Injury After Coronary Angiography and PCI: Insights from a Randomized Trial

By MedXY 08/13/2025

A multicenter randomized trial demonstrates that delayed remote ischemic preconditioning 24 hours prior to coronary angiography or PCI significantly lowers the incidence of contrast-associated acute kidney injury in high-risk patients.

Diabetes & Endocrinology Nephrology news Specialties

Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial

By MedXY 08/13/2025

The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818 diverse participants.

Clinical Updates Nephrology news Specialties

Urine Biomarkers Predict Kidney Function Recovery After Ambulatory Acute Kidney Injury in Blood Pressure Treatment

By MedXY 08/13/2025

Urine biomarkers reflecting glomerular injury and tubular dysfunction can predict kidney function recovery after ambulatory acute kidney injury in hypertensive patients, aiding clinical decision-making during blood pressure management.

Cardiology Clinical Updates Nephrology Neurology news Specialties

OPTIMAS Trial: Early vs. Delayed Anticoagulation in Acute Ischemic Stroke with Atrial Fibrillation and Chronic Kidney Disease

By MedXY 08/13/2025

The OPTIMAS trial shows that chronic kidney disease does not alter the safety or efficacy of early direct oral anticoagulant use after acute ischemic stroke with atrial fibrillation, supporting early initiation regardless of kidney status.

Cardiology Nephrology Specialties

Examining the Link Between Obesity and Kidney Outcomes in Heart Failure with Preserved Ejection Fraction

By MedXY 08/11/2025

A pooled analysis of four heart failure trials explores the relationship between obesity and kidney outcomes, revealing waist circumference and waist-to-height ratio as key risk factors, while body mass index showed no significant association.

Cardiology Nephrology news Specialties

ARBs versus Dihydropyridine CCBs : Which Protects the Heart and Which Safeguards the Kidneys?

By MedXY 08/10/2025

Comparative review of angiotensin receptor blockers (ARBs, “沙坦”) and dihydropyridine calcium‑channel blockers (DHP‑CCBs, “地平类”) focused on organ protection—kidney, heart and brain—and practical selection based on comorbidity and evidence.

Clinical Updates Diabetes & Endocrinology Nephrology news Specialties

Dual Renal Protection: Finerenone Plus Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

By MedXY 08/09/2025

Combining finerenone with empagliflozin provides superior reduction in albuminuria for patients with chronic kidney disease and type 2 diabetes, without increased adverse events.

Clinical Updates Medical News Nephrology Specialties

Managing Chronic Kidney Disease-Associated Pruritus: Advances and Clinical Strategies

By MedXY 07/30/2025

CKD-associated pruritus affects up to 85% of dialysis patients and significantly impairs quality of life. Stepwise management, including novel therapies like nemolizumab, is essential for effective symptom control and improved patient outcomes.